Although Gail Wilensky PhD, senior fellow at Project HOPE, is doubtful that imposing work requirements in Medicaid will have much effect, either positive or negative on enrollment, but she thinks it will help bring to the table states that were not otherwise willing to expand Medicaid.
Although Gail Wilensky PhD, senior fellow at Project HOPE, is doubtful that imposing work requirements in Medicaid will have much effect, either positive or negative on enrollment, but she thinks it will help bring to the table states that were not otherwise willing to expand Medicaid.
Transcript
What impact do you think the Trump administration’s willingness to provide waivers to states for their Medicaid programs could have on healthcare outcomes?
I think there is a philosophical issue that many Republicans, including the Trump administration, have taken, which is that states ought to be allowed to make some adjustments in programs so that it best suits the needs of their state citizenry as the elected officials see it. In this case, it may be ironic that it is the ability to impose work requirements that may be what draws some of the states that have been reluctant to expand their Medicaid program into an expansion.
I’m somebody who has taken the position that I’m doubtful that the work requirement will have nearly as much effect positive or negative as either it’s supporters or detractors claim. But I think if it brings people to the table who have not otherwise been willing to expand Medicaid, we ought to realize this a great step forward. The problem that people who are supporting the expansion don’t fully appreciate is that only some of the populations on Medicaid are able to work and many of those who are able to work are actively either working or seeking work. Allowing them to have alternatives, community service, training, in addition to actually being employed means that it will allow people who are looking but are unable to find work at the present time not to lose their Medicaid coverage which is very important. I think there may be a surprise that the population is not bigger than it is, but if it’s enough to allow a state that has been reluctant to expand to embrace the Medicaid expansion, it is well worth the effort.
If you actually cut people off from Medicaid because they don’t comply, it is an area that you ought to have mixed feelings about. It’s one thing to take away some financial support either through food stamps or welfare payments to take away needed medical care is a more draconian measure and if people are sick enough or become sick enough they can always show up in the very expensive emergency room which is hardly a game for anybody, the state or the individuals. So, I hope it is an effective club but not one that will actually be taken and used in terms of taking away Medicaid coverage.
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Neurologists Share Tips for Securing Patient Access to Gene Therapies
March 19th 2025Tenacious efforts at every level, from the individual clinician to the hospital to the state to Congress, will be needed to make sure patients can access life-saving gene therapies for neuromuscular diseases.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
EMBARK Data Show Continued Improvements With DMD Gene Therapy
March 19th 2025Data from the EMBARK trial of delandistrogene moxeparvovec in patients with Duchenne muscular dystrophy (DMD) show that benefits in functional outcomes, gene expression, and muscle imaging persist 2 years after receiving the gene therapy.
Read More
How Access to SMA Treatment Varies Globally and by Insurance Type
March 18th 2025Posters presented at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference show that therapeutic advances in treating spinal muscular atrophy (SMA) are not uniformly making it into the hands of patients who could benefit.
Read More